Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin + moxifloxacin + linezolid versus standard treatment for drug-susceptible smear-positive pulmonary tuberculosis
2021-001626-22Phase 2Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin, moxifloxacin and linezolid in pulmonary tuberculosis (TB) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Mar 2022; status: active.
02
Drugs
rifampicinmoxifloxacinlinezolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2021-001626-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001626-22.